The current role of photodynamic therapy in oesophageal dysplasia and cancer

Photodiagnosis and Photodynamic Therapy

Volumn 4, Issue 3, 2007, Pages 151-159

  Gray, Joanna ^a   Fullarton, Grant ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Barrett's epithelium; High grade dysplasia; Oesophageal cancer; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; OMEPRAZOLE; PHOTOFRIN; TEMOPORFIN;

ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; BLEEDING; BRACHYTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSIMETRY; DYSPHAGIA; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS MALFORMATION; ESOPHAGUS RESECTION; ESOPHAGUS STRICTURE; EXTERNAL BEAM RADIOTHERAPY; FEVER; FISTULA; HEART ATRIUM FIBRILLATION; HUMAN; LEUKOCYTOSIS; NEODYMIUM LASER; PERFORATION; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PHOTOTOXICITY; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; STENOSIS; SUPRAVENTRICULAR TACHYCARDIA;

EID: 34547772812     PISSN: 15721000     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2007.04.003     Document Type: Review

References (77)

1. Dougherty T.J. Activated dyes as anti-tumour agent. J Natl Cancer 52 (1974) 1333-1336
2. Barr H., Dix A.J., Kendall C., and Stone N. Review article: the potential role for photodynamic therapy in the management of upper gastrointestinal disease. Aliment Pharmacol Therapeut 15 (2001) 311-321
3. Dougherty T.J. Photosensitisation of malignant tumours. Sem Surg Oncol 2 1 (1986) 24-37
4. Gollnick S., Vaughan L., and Henderson B. Generation of effective antitumour vaccines using photodynamic therapy. Cancer Res 62 (2002) 1604-1608
5. Van Duijnhoven F.H., Aalbers R.I., Rovers J.P., Terpstra O.T., and Kuppen P.J. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 207 2 (2003) 105-113
6. Pech O., Gossner L., May A., et al. Long-term results of photodynamic therapy with 5 Aminolevulinic acid for superficial Barrett's cancer and high grade intraepithelial neoplasia. Gastrointest Endosc 62 1 (2005) 24-30
7. Bruce S. Photodynamic therapy: another option in cancer treatment. Clin J Oncol Nurs 5 (2001 Number 3) 95-99
8. Hahn S.M., Putt M.E., Metz J., et al. Photofrin uptake in the tumour and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res 12 18 (2006) 5464-5470
9. Perry Y., Epperly M.W., Fernando H.C., et al. Photodynamic therapy induced oesophageal stricture ... an animal model: from mouse to pig. J Surg Res 123 1 (2005) 67-74
10. Cramers P., Ruevekamp M., Oppelaar H., Dalesio O., Baas P., and Stewart F.A. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer 88 2 (2003) 283-290
11. Wagnieres G., Hadjur C., Grosjean P., et al. Clinical evaluation of the cutaneous phototoxicity of 5,10,15,20-tetra (m-hydroxyphenyl) chlorine. Photochem Photobiol 68 (1998) 382-387
12. Lovat L.B., Jamieson N.F., Novelli M.R., et al. Photodynamic therapy with m-tetrahydroxyphenylchlorin for high grade dysplasia and early cancer in Barrett's columnar lined oesophagus. Gastrointest Endosc 62 4 (2005) 617-623
13. Etienne J., Dorme N., Bourg-Heckly G., Raimbert P., Flejou J.F., and Flijou J.F. Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorine for intramucosal adenocarcinoma and high grade dysplasia in Barrett's oesophagus. Gastrointest Endosc 59 7 (2004) 880-889
14. Barr H., Kendall C., and Stone N. Photodynamic therapy for oesophageal cancer: a realistic option. Technol CancerRes Treat 2 1 (2003) 65-75
15. Brown S.G., and Rogowska A.Z. New photosensitizers for photodynamic therapy in gastroenterology. Canadian Journal Gastroenterology 13 (1999) 389-392
16. Heier S.K., Rothman K.A., Heier L.M., and Rosenthal W.S. Photodynamic therapy for obstructing oesophageal cancer: light dosimetry and randomised comparison with Nd:YAG laser therapy. Gastroenterology 109 1 (1995) 63-72
17. Craig C., Macpherson M., Hodgson H., Gray J., Zammit M., and Fullarton G. Photodynamic therapy is of benefit in treatment of early oesophageal carcinoma. Gastroenterology 130 4 (2006) 414
18. Panjehpour M., Overhalt B.F., Phan M.N., and Haydek J.M. Optimisation of light dosimetry for photodynamic therapy of Barrett's oesophagus: efficacy vs. incidence of stricture after treatment. Gastrointest Endosc 61 1 (2005) 13-18
19. The UK Clinical PDT Study Group, Clinical guidelines for performing photodynamic therapy (PDT) on patients with bronchopulmonary or oesophageal cancer; 2002.
20. Mordon S., and Maunoury V. Using white light during photodynamic therapy: visualization only or treatment?. Eur J Gastroenterol Hepatol 18 7 (2006) 765-771
21. Moghissi K., Dixon K., Hudson E., and Stringer M. Photodynamic therapy of oesophageal cancer. Lasers Med Sci 10 (1995) 67-71
22. Litle V.R., Luketich J.D., and Christie N.A.E.-A. Photodynamic therapy as palliation for oesophageal cancer: experience in 215 patients. Ann Thorac Surg 76 (2003) 1687-1692
23. McCaughan Jr. J.S. Photodynamic therapy for obstructive oesophageal malignancies. Diagn Theraput Endosc 5 (1999) 174
24. Wolfsen H.C., Hemminger L.L., Wallace M.B., and Devault K.R. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Theraput 20 (2004) 1125-1131
25. Lightdale C.J., Heier S.K., Marcon N.E., et al. Photodynamic therapy with porfirmer sodium versus thermal ablation with Nd YAG laser for palliation of oesophageal cancer; a multicentre randomized trial. Gastrointest Endosc 42 (1996) 507-512
26. Etienne J., Dorme N., Bourg-Heckly G., Raimbert P., and Flijou J. Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorine for intramucosal adenocarcinoma and HGD in Barrett's oesophagus. Gastrointest Endosc 59 7 (2004) 880-889
27. Gossner L., Stolte M., Sroka R., et al. Photodynamic ablation of HGD and early cancer in Barrett's oesophagus by means of 5 aminolevulinic acid. Gastroenterology 114 3 (1998) 448-455
28. Corley D.A., and Buffler P.A. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the cancer incidence in five continents database. Int J Epidemiol 30 (2001) 1415-1425
29. National Statistics. Cancer Atlas of the UK and Ireland 1991-2000. Office for National Statistics (ONS); 2006.
30. Cancer Research UK. Information Resource Centre; 2004. Weblink http://info.cancerresearchuk.org.
31. Parkin D.M., Bray F., Ferlay J., et al. Estimating the World cancer burden: globocan. Int J Cancer 94 (2000) 163-166
32. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide Incidence of Eighteen major Cancers in 1985. Int J Cancer 54 (1993) 594-606
33. Phull P.S., Salmon C.A., Park K.G.M., Rapson T., Thompson A.M., and Gilbert F.J. Age threshold for endoscopy and risk of missing upper gastrointestinal malignancy-data from the Scottish Audit of gastric and oesophageal cancer (SAGOC). Aliment Pharmacol Theraput 23 2 (2006) 229-233
34. Gilbert FJ, Park K, Thompson AM. Scottish Audit of Gastric and Oesophageal Cancer Report 1997-2000. A prospective audit 2002. Scottish Audit of Gastric and Oesophageal Cancer Steering Group, Edinburgh.
35. Rudolph R.E., Vaughan T.L., Storer B.E., et al. Effect of segment length on risk for neoplastic preogression in patients with Barretts oeophaugus. Ann Intern Med 132 (2000) 612-620
36. Van den Bogart, Van Hillergeersberg R., De Bruin R.W.F., and Tilanus H. Barrett's oesophagus: pathophysiology, diagnosis and management. Scand J Gastroenterol 33 (1998) 449-453
37. Wolfsen H.C. Present status of photodynamic therapy for high grade dysplasia in Barrett's oesophagus. J Clin Gastroenterol 39 3 (2005) 189-202
38. Tseng E.E., Wu T.T., Yeo C.J., et al. Barrett's oesophagus with high grade dysplasia: surgical results and long term outcome: an update. J Gastrointest Surg 7 (2003) 164-170 discussion 170-171
39. Portale G., Hagen J., Peters J., et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 202 4 (2006) 588-596
40. Muller J.M., Erasmi H., Stelzner M., Zieren U., and Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg 77 (1990) 845-857
41. Rindani R., Martin C.J., and Cox M.R. Transhiatal versus Ivor Lewis oesophagectomy: is there a difference?. Austr NZ J Surg 69 (1999) 187-194
42. Chang L.C., Oelschlager B.K., Quiroga E., et al. Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surveillance for Barrett's esophagus. J Gastroint Surg 10 3 (2006) 341-346
43. Heitmiller R.F., Redmond M., and Hamilton S.R. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 224 1 (1996) 66-71
44. Thomas T., Richards C.J., De Caestecker J., and Robinson R.J. High grade dysplasia in Barrett's oesophagus; natural history and review of clinical practise. Aliment Pharmacol Theraput 21 6 (2005) 747-755
45. Brown S.B., and Walker E.A. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5 8 (2004) 497-508
46. Kelty C.J., Ackroyd R., Brown N.J., Stephenson T.J., Stoddart C.J., and Reed M.W. Endoscopic ablation of Barrett's oesophagus: a randomized controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol 20 11-12 (2004) 1289-1296
47. Ragunath K., Krasner N., Raman V.S., Haqqani M.T., Phillips C.J., and Cheung I. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomised prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol 40 7 (2005 July) 750-758
48. NICE Guidelines 2006. Interventional Procedure Programme. Interventional procedures overview of photodynamic therapy for high grade dysplasia for Barrett's oesophagus.
49. Overholt B.F., Panjehpour M., and Halberg D.L. Photodynamic therapy for Barrett's oesophagus with dysplasia and or early stage carcinoma: long term results. Gastrointest Endosc 58 2 (2003) 183-188
50. Wolfsen H.C., Woodward T.A., and Raimondo M. Photodynamic therapy for dysplastic Barrett's oesophagus and early oesophageal adenocarcinoma. Mayo Clinic Proc 77 11 (2002) 1176-1181
51. Christophorus, Foroulis N., and Thorpe A.C. Photodynamic therapy (PDT) in Barrett's oesophagus with dysplasia or early cancer. Eur J Cardio-Thorac Surg 29 1 (2006) 30-34
52. Overholt B.F., Lightdale C.J., Wang K., et al. International multicentre partially blinded randomised study into the efficacy of photodynamic therapy (PDT) using Porfirmer sodium (POR) for the ablation of high grade dysplasia (HGD) in Barrett's oesophagus (BE):Results of a 24 month follow up. Gastroenterology 124 Suppl 1 (2003) A20:151
53. Overholt B., Wang K., Burdick S., et al. A 5 year randomised phase 3 trial of efficacy and safety of photodynamic therapy using porirmer sodium in high grade dysplasia in Barrett's esophagus. Gastroenterology 130 4 (2006)
54. Gossner L., May A., Sroka R., Stolte M., Hahn E.G., and Ell C. Photodynamic destruction of high grade dysplasia and early carcinoma of the esophagus after the oral administration of 5-aminolevulinic acid. Cancer 86 10 (1999) 1921-1928
55. Pech O., Gossner L., May A., et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc Jul 62 1 (2005) 24-30
56. Barr H., Shepherd N.A., Dix A., Roberts D.J.H., Tan W.C., and Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 348 9027 (1996) 584-585
57. Biddlestone L.R., Barham C.P., Wilkinson S.P., et al. The histology of treated Barrett's oesophagus. Am J Pathol 22 (1998) 239-245
58. Barham C.P., Jones R.L., Biddlestone L.R., Hardwick R.H., and Barr H. Photothermal laser ablation of Barrett's oesophagus and histological evidence of squamous re-epithelialisation. Gut 41 3 (1997) 281-284
59. Van Laethem J.L., Cremner M., Peny M.O., et al. Complete eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 43 (1998) 747-752
60. Van Laethem J.L., Peny M.O., Salmon I., Cremer M., and Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 46 4 (2000) 574-577
61. Hur C., Nishioka N.S., and Gazelle G.S. Cost-effectiveness of photodynamic therapy for treatment of Barrett's oesophagus with high grade dysplasia. Dig Dis bSci 48 7 (2003) 1273-1283
62. Zhang X., Watson D.I., Lally C., and Bessell J.R. Endoscopic ultrasound for pre-operative staging of oesophageal carcinoma. Surg Endosc 19 12 (2005) 1618-1621
63. Sibille A., Lambert R., Souquet J.C., Sabben G., and Descos F. Long term survival after photodynamic therapy for oesophageal cancer. Gastroenterology 108 2 (1995) 337-344
64. Buttar N.S., Wang K.K., Lutzke L.S., Krishnadath K.K., and Anderson M.A. Combined endoscopic mucosal resection and photodynamic therapy for oesophageal neoplasia within Barrett's oesophagus. Gastrointest Endosc 54 6 (2001) 682-688
65. Wolfsen H.C., Hemminger L.L., Raimomdo M., and Woodward T.A. Photodynamic therapy and endoscopic mucosal resection for Barrett's dysplasia and early oesophageal adenocarcinoma. South Med J 97 9 (2004) 827-830
66. Edler D.G., and Baron T.H. Endoscopic palliation of malignant dysphagia. Mayo Clinic Proc 76 7 (2001) 731-738
67. Jin M., Yang B., Zhang W., and Wang Y. Photodynamic therapy for upper gastrointestinal tumours over the past 10 years. Sem Surg Oncol 10 (1994) 111-113
68. Heier S.K., Rothman K.A., Heier L.M., and Rosenthal W.S. Photodynamic therapy for obstructing oesophageal cancer: light dosimetry and randomized comparison with Nd:YAG laser therapy. Gastroenterolgy 109 (1995) 63-73
69. Fullarton G.M. Photodynamic therapy for advanced oesophageal carcinoma. Proceedings of the international congress and symposium (series 255) on photodynamic therapy-applications in gastroenterology and pulmonology (2004)
70. O'Donnell C.A., Fullarton G.M., Watt E., et al. Randomaised clinical trial comparing self expanding metallic stents with plastic endoprotheses in the palliation of oesophageal cancer. Br J Surg 89 (2002) 985-992
71. Zoepf T., Jakobs R., Arnold J.C., Apel D., Rosenbaum A., and Riemann J.F. Photodynamic therapy for palliation of non-resectable bile duct cancer -Preliminary results with a new diode laser system. Am J Gastroenterol 96 7 (2001) 2093-2097
72. Sanfilippo N.J., His A., Denittis A.S., et al. Toxicity of photodynamic therapy after combined external beam radiotherapy and intra-luminal brachytherapy for carcinoma of the upper aerodigestive tract. Lasers Surg Med 28 3 (2001) 278-281
73. Maier A., Anegg U., Fell B., et al. Effect of photodynamic therapy in a multimodal approach for advanced carcinoma of the gastroesophageal junction. Lasers Surg Med 26 5 (2000) 461-466
74. Schaffer M., Erti-Wagner, Schaffer P.M., et al. The application of Photofrin 2 as a sensitising agent for ionizing radiation-a new approach in tumour therapy. Curr Med Chem 12 10 (2005) 1209-1215
75. Schaffer M., Erti-Wagner B., Schaffer P.M., et al. Feasibility of Photofrin 2 as a radiosensitizing agent in solid tumous-preliminary results. Oncology 29 11 (2006) 514-519
76. O'Donnell C.A., Gray J., Hodgson H., MacPherson M., Zammit M., and Fullarton G. A cost comparison of photodynamic therapy and metallic stents in the palliation of oesophageal cancer. Photodyn Therapy Photodiagn 4 1 (2007) 65-70
77. Peng Q., Warloe T., Moan J., et al. Antitumour effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of Photofrin in human tumour xenografts. Cancer Res 61 15 (2001) 5824-5832